Immunotherapy · 2019
Immunotherapy plus surgery/radiosurgery is associated with favorable survival in patients with melanoma brain metastasis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amaral Teresa, Tampouri Ioanna, Eigentler Thomas, Keim Ulrike, Klumpp Bernhard, Heinrich Vanessa, Zips Daniel, Paulsen Frank, Gepfner-Tuma Irina, Skardelly Marco, Tatagiba Marcos, Tabatabai Ghazaleh, Garbe Claus, Forschner Andrea
Аннотация
AIM: Melanoma brain metastases (MBM) are associated with a dismal prognosis. Few clinical trials evaluated the impact of immunotherapy (IT) and targeted therapy (TT) alone or in combination with surgery and radiotherapy in this population.
PATIENTS & METHODS: Retrospective analysis of data from 163 patients diagnosed with MBM between January 2014 and December 2016. Prognostic factors of overall survival were analyzed using Kaplan-Meier survival curves, classification and regression tree and multivariate Cox regression analysis.
RESULTS: The median follow-up was 25 months; median overall survival (mOS) for all patients was 7 months. For patients receiving IT, the mOS was 13 months and 7 months for patients receiving TT or chemotherapy (CT). The mOS for patients treated with surgery/radiosurgery in combination with IT, TT and CT was 25, 14 and 11 months, respectively.
CONCLUSION: New systemic therapies, especially IT, improve mOS in patients with MBM, particularly when combined with surgery/radiosurgery upfront.
PATIENTS & METHODS: Retrospective analysis of data from 163 patients diagnosed with MBM between January 2014 and December 2016. Prognostic factors of overall survival were analyzed using Kaplan-Meier survival curves, classification and regression tree and multivariate Cox regression analysis.
RESULTS: The median follow-up was 25 months; median overall survival (mOS) for all patients was 7 months. For patients receiving IT, the mOS was 13 months and 7 months for patients receiving TT or chemotherapy (CT). The mOS for patients treated with surgery/radiosurgery in combination with IT, TT and CT was 25, 14 and 11 months, respectively.
CONCLUSION: New systemic therapies, especially IT, improve mOS in patients with MBM, particularly when combined with surgery/radiosurgery upfront.
Предметные рубрики MeSH
AgedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsBrain NeoplasmsCTLA-4 AntigenFemaleFollow-Up StudiesHumansMaleMelanomaMiddle AgedNeoplasm MetastasisNeoplasm StagingProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsRadioimmunotherapyRadiosurgeryRetrospective StudiesSurvival AnalysisTreatment Outcome